



HAL
open science

Factors Associated With Severe Nonmeningitis Invasive Pneumococcal Disease in Adults in France

Kostas Danis, Emmanuelle Varon, Agnès Lepoutre, Cécile Janssen, Emmanuel Forestier, Olivier Epaulard, Yohan N'guyen, Anaïs Labrunie, Philippe Lanotte, Alain Gravet, et al.

► **To cite this version:**

Kostas Danis, Emmanuelle Varon, Agnès Lepoutre, Cécile Janssen, Emmanuel Forestier, et al.. Factors Associated With Severe Nonmeningitis Invasive Pneumococcal Disease in Adults in France. Open Forum Infectious Diseases, 2019, 6 (12), 10 p. 10.1093/ofid/ofz510 . hal-03267067

HAL Id: hal-03267067

<https://hal.science/hal-03267067>

Submitted on 22 Jun 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Factors Associated With Severe Nonmeningitis Invasive Pneumococcal Disease in Adults in France

Kostas Danis,^{1,2} Emmanuelle Varon,^{2,3} Agnès Lepoutre,¹ Cécile Janssen,³ Emmanuel Forestier,⁴ Olivier Epaulard,⁵ Yohan N'Guyen,⁶ Anaïs Labrunie,^{7,8} Philippe Lanotte,⁹ Alain Gravet,¹⁰ Isabelle Pelloux,⁵ Pascal Chavanet,¹¹ SIIPA Group, Daniel Levy-Bruhl,¹ Marie-Cécile Ploy,^{7,12} and Jacques Gaillat³

¹Santé Publique France (SpFrance), the French National Public Health Agency, Saint-Maurice, France, ²National Centre for Pneumococci, Centre Hospitalier Intercommunal Créteil, Créteil, France, ³Hospital Centre Ancey Genevois, Ancey, France, ⁴Hospital Centre Chambéry, Chambéry, France, ⁵University Hospital Centre Grenoble, Grenoble, France, ⁶University Hospital Centre Reims, Reims, France, ⁷University Hospital Centre Limoges, Regional Observatories for Pneumococci (Observatoires Régionaux du Pneumocoque), Limoges, France, ⁸University Hospital Centre Limoges, CEBIMER, Limoges, France, ⁹University Hospital Centre Tours, Tours, France, ¹⁰Hospital Emile Müller Mulhouse, Mulhouse, France, ¹¹Hospital du Bocage Dijon, Dijon, France, and ¹²University Limoges, INSERM, CHU Limoges, RESINFIT, U1092, F-87000, Limoges, France

Background. In France, pneumococcal vaccination in adults is recommended for risk groups (chronic conditions/immunosuppression). We conducted a study on invasive pneumococcal disease (IPD) in adults to identify factors associated with disease severity and death.

Methods. We included IPD cases, excluding meningitis, from 25 acute care hospitals in 6 regions. We defined severe cases as those with shock or severe sepsis or intensive care unit admission/mechanical ventilation. We included deaths occurring within 30 days of hospitalization. Infectious disease specialists collected clinical/microbiological data on cases.

Results. During 2014–2017, 908 nonmeningitis IPD cases were diagnosed; 48% were severe, 84% had comorbidities, 21% died. Ninety percent of cases with comorbidities who previously sought health care were not vaccinated against pneumococcus. Compared with previously healthy cases, the risk of severe IPD increased from 20% (adjusted risk ratio [aRR], 1.2; 95% confidence interval [CI], 1.0–1.4) in cases with 1–2 chronic diseases to 30% (aRR, 1.3; 95% CI, 1.0–7.0) in those with >2 chronic diseases. Among risk groups, 13-valent pneumococcal conjugate vaccine (PCV13) serotypes and 23-valent pneumococcal polysaccharide vaccine (PPSV23) nonPCV13 serotypes were more likely to induce severe IPD compared with nonvaccine serotypes (aRR, 1.5; 95% CI, 1.3–1.9; aRR, 1.3; 95% CI, 1.0–1.5, respectively).

Conclusions. We observed a cumulative effect of concurrent comorbidities on severe IPD. Vaccine serotypes were more likely to induce severe IPD among risk groups. The missed opportunities for vaccination underscore the need to enhance vaccination in risk groups.

Keywords. invasive pneumococcal disease; pneumococcal conjugate vaccine; surveillance; *Streptococcus pneumoniae*; mortality; outcome.

Streptococcus pneumoniae or pneumococcus remains an important cause of mortality among adults worldwide [1–3]. Pneumococci differ markedly in their pathogenicity according to their serotype, with the existence of serotype-specific differences in mortality following invasive pneumococcal disease (IPD) [4–7]. Some serotypes are associated with increased risk of invasiveness or disease severity [8]. Besides serotypes, host factors are also crucial in developing IPD, with certain underlying medical conditions or risk behaviors such as smoking or alcohol abuse having been associated with IPD [9, 10].

IPD-related mortality has been previously associated with increasing age and clinical complications (such as sepsis and septic shock) [11, 12]. Several studies have reported an increase in IPD incidence with increasing number of underlying conditions [9, 13]. However, the role of comorbidities and specifically the cumulative effect of concurrent comorbidities on poor outcomes among IPD patients, accounting for the potentially confounding effect of aging, is less well known [14].

In France, 7-valent pneumococcal conjugate vaccine (PCV7) was recommended for children at risk aged ≤2 years in 2003 and for all children ≤2 years in 2006. In 2010, PCV7 was replaced by PCV13 for all children ≤2 years. Since 2011, PCV13 coverage for the primo-vaccination series at 9 months of age has been exceeding 91% (<https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/articles/donnees-de-couverture-vaccinale-pneumocoque-par-groupe-d-age>). PPSV23 vaccination has been recommended for children aged ≥2 years and adults with comorbidities for decades. During 2012–2016, pneumococcal vaccination with PCV13 followed by PPSV23 was recommended for immunocompromised or

Received 29 August 2019; editorial decision 22 November 2019; accepted 28 November 2019.
Correspondence: Kostas Danis, MD, MSc, PhD, Santé publique France, 12, rue du Val-d'Osne, 94415 Saint-Maurice cedex, France (costas.danis@santepubliquefrance.fr).

Open Forum Infectious Diseases®

© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofz510

immunosuppressed children aged ≥ 5 years, adults, and those with a cochlear implant, regardless of age (high-risk patients) or for children aged 2–5 years with medical chronic or immunosuppressive conditions, if they had not previously received PCV13 [15]. For immunocompetent adults with medical chronic conditions or history of alcoholism or current smoking (at-risk patients), the previous strategy (1 dose of PPSV23) was maintained. In 2017, recommendations were harmonized for both high-risk and at-risk patients based on the combined schedule (PCV13 and PPSV23 in series) [16]. To estimate the impact of these updated recommendations for vaccination, the identification of the population groups most likely to develop severe disease or poor outcomes following IPD at baseline was required.

Between June 2014 and December 2017, we conducted a prospective study among ≥ 18 -year-old patients with nonmeningitis IPD in France to describe their underlying diseases and identify factors associated with disease severity and fatality.

METHODS

Study Population

The study was based on the French network of 23 regional laboratories (Regional Observatories of Pneumococcus [ORP]), which coordinate microbiological surveillance of IPD in children and adults at the regional level [18]. Twenty-five acute care hospitals from 6 of the 13 French regions of metropolitan France (population 4 716 969, accounting for 7% of the French adult population) participated in the study; all serve as referent facilities for the residents of the study area and include intensive care units (ICUs) to ensure ability to care for severe infectious diseases. During the study period, PCV13 coverage for 3 doses at 24 months of age was $>90\%$ in the study area (https://geodes.santepubliquefrance.fr/#c=indicator&i=cv_cs24_pneumo_cv_pneu3&s=2017&t=a01&view=map2).

Definitions

We defined as cases IPD patients with isolation of *S. pneumoniae* from a normally sterile site (blood, pleural fluid, joint fluid, peritoneal fluid), according to the 2012 European Commission (EC) case definition [18]. We excluded pneumococcal meningitis cases, as those were monitored in another dedicated study. We used 2 main outcomes: severe IPD and death/survival. Severe cases were defined as nonmeningitis IPD patients who were either admitted to an ICU or needed mechanical ventilation or had severe sepsis or septic shock. We used the 2001 International Sepsis Conference definition for severe sepsis (ie, sepsis and lactates >4 mmol/L or hypotension before fluid resuscitation or ≥ 1 organ dysfunction [respiratory: $\text{PaO}_2/\text{FiO}_2 < 300$; or renal: serum creatinine >176 $\mu\text{mol/L}$; or coagulation: $\text{INR} > 1.5$; or liver: $\text{INR} > 4$, bilirubin > 78 $\mu\text{mol/L}$; or thrombocytopenia: $<105/\text{mm}^3$; or cognitive functions: <13 on

Glasgow Coma Scale]) and for septic shock (severe sepsis and hypotension despite fluid resuscitation, 20–40 mL/kg, >40 mL/kg) [19]. We defined as deaths attributable to nonmeningitis IPD those occurring during hospitalization within 30 days of admission. Cases with comorbidities were those belonging to the 2 risk groups according to the French recommendations for pneumococcal vaccination in persons aged >5 years (high-risk or at-risk) [17]. We defined multiple comorbidities as >2 chronic conditions, excluding smoking and alcoholism.

Laboratory Methods

S. pneumoniae isolates were identified in the microbiology laboratory of each participating hospital. All *S. pneumoniae* isolates were transferred for identity confirmation to the National Reference Centre for Pneumococci (NRCP), where serotyping was performed with the use of latex particles sensitized with pool, group, type, and factor antisera provided by the Statens Serum Institut (Copenhagen, Denmark). This panel of antisera enabled recognition of 92 known serotypes. Susceptibility to penicillin G, amoxicillin, cefotaxime, and ceftriaxone was determined at the NRCP using the broth dilution method, and susceptibility to erythromycin was determined using the disk diffusion method according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [20]. The results were interpreted according to EUCAST breakpoints (version 7.1, 2017) [20]. Intermediate or resistant isolates were considered nonsusceptible.

Data Collection

Once nonmeningitis IPD cases were diagnosed at a participating hospital, infectious disease specialists prospectively collected data on demographics, hospitalization dates, clinical manifestations, underlying conditions, and disease outcomes of all diagnosed cases, using a bespoke data collection form. Vaccination status data were collected by infectious diseases specialists using patients' vaccination cards, medical records, and patient general practitioner (GP) or family interviews.

Statistical Analysis

We calculated proportions using the total number of nonmissing values as the denominator, age-specific incidence, case fatalities (CFs), and risk ratios (RRs). We classified serotypes according to their potential for causing invasive disease and death, as previously described [21–26]. Serotypes with previous strong associations with fatality included serotypes 3, 19A, 12F, 9N, 24F, 11A, 20, 23A, 10A, 19F, 6C, 35B, 15B/C, 35F, 31, 16F, 17F, 14, 6A, 6B, 18C, and 23F; medium effects included serotypes 22F, 15A, 33F, and 9V; low or no association included serotypes 8, 7F, 1, 4, and 5. We estimated survival probabilities using Kaplan-Meier survival curves. To identify factors independently associated with survival, we calculated adjusted hazard ratios (aHRs) using parametric survival analysis assuming a Weibull distribution.

To compare individual serotypes, we used serotype 8 as a reference, which was the second most frequent serotype that had not been previously associated with severe disease. To identify factors independently associated with severity, we calculated adjusted RRs (aRRs) using multivariable binomial regression. We included in the initial regression models all variables with a *P* value < .30. To simplify the models, we removed variables 1 at a time depending on the significance testing (*P* < .05) by the likelihood ratio (LR) test. We performed the analysis using STATA software (version 12; Stata Corporation, TX, USA).

Ethical Issues

The French National Data Protection Commission approved the data collection procedures (approval reference No. 909028). The study did not require further ethical committee approval, as it was part of ongoing surveillance.

RESULTS

Descriptive Characteristics

Between June 2014 and December 2017, 908 (67%) nonmeningitis IPD cases were recorded. Their age ranged from 18 to 101 years (median, 71); 53% (480/908) were male. The age and serotype distribution of the cases in the study did not differ significantly from those reported from metropolitan France during the same period through the ORP surveillance system (data not shown). In addition, the annual IPD incidence rates in the study area were similar to those in metropolitan France.

Severe Outcomes

Of all cases, 48% (431/899) had severe nonmeningitis IPD, 31% were admitted to an intensive care unit (ICU; median stay [range], 5 [1–70] days); 74% (669/908) presented with pneumonia; 12% (108/908) bacteremia without known focus, 7% (67/908) with pneumonia and/or pleuritis, and the remaining 7% (64/908) with infections in other sites (Table 1). The median duration of hospitalization of cases (range) was 9 (0–432) days. Of all cases, 22% (201/908) died during hospitalization and 21% (188/908) died within 30 days after admission, 33% (61/188) of whom died within the first 48 hours after admission. The median time to death from date of admission (range) was 4 (0–115) days.

Underlying Conditions

Of cases, 84% belonged to a risk group; 37% (335/908) were high risk, and 47% (429/908) were at risk. The prevalence of multiple comorbidities was overall 31%, ranging from 16% among cases <65 years of age to 36% among cases ≥65 years of age (*P* ≤ .001) (Table 1). Compared with older cases, <65-year-olds were more likely to be admitted to an ICU and to be current smokers or alcoholics, but less likely to suffer from heart disease, diabetes, and malnutrition (Table 1). Compared with at-risk cases, high-risk cases were less likely to live in a long-term care facility

(LTCF) or present with shock, but more likely to have >2 at-risk conditions (Table 1).

Serotype Distribution and Antimicrobial Resistance

Of the 833 (92%) cases with a known serotype, 249 (30%) had a PCV13 serotype, 353 (42%) had a PPSV23nonPCV13 serotype, and 231 (28%) had a nonvaccine serotype; 32% of high-risk cases were due to a PCV13 serotype, compared with 26% of at-risk cases (*P* < .001). The most frequent serotypes were 3 (15%), 8 (9%), 22F (8%), and 19A (7%). Among cases with antimicrobial susceptibility tested, 20% (167/836) were nonsusceptible to penicillin (Table 1).

Vaccination Status

Among high-risk or at-risk cases, 10% were vaccinated against pneumococcus within the previous 5 years, 4% with PCV13 and 7% with PPSV23 (Table 1). Of those cases with comorbidities who were hospitalized or consulted a specialist or general practitioner in the previous year, 10% received a pneumococcal vaccine.

Factors Associated With Fatality

Thirty-day intrahospital case fatality did not differ significantly (*P* = .232) among at-risk cases (20%) and high-risk cases (24%). Case fatality was 3.7 (RR, 3.7; 95% confidence interval [CI], 2.7–5.0) times higher among cases with severe disease. Lower survival probabilities were observed among cases with severe disease and cases with >2 at-risk conditions (Figure 1). Case fatality of current smokers or alcoholics did not differ significantly from that of nonsmokers or nonalcoholics (RR, 0.47; 95% CI, 0.30–2.1; RR, 0.74; 95% CI, 0.47–1.1, respectively).

In the final survival analysis model, case fatality increased with increasing age (aHR per year of age, 1.04; 95% CI, 1.03–1.06; *P* < .001). Compared with others, fatality was higher among cases with >2 chronic at-risk conditions, among those with malignant solid tumors diagnosed within the last 5 years, those with severe sepsis or shock, and those residing in an LTCF (Table 2). In contrast, cases admitted to an ICU and those with a penicillin-nonsusceptible isolate were less likely to die (Table 2). Similarly, case fatality among cases who received at least 1 dose of antipneumococcal vaccine (PCV13 or PPSV23) or PCV13 alone was 78% (aHR, 0.22; 95% CI, 0.09–0.56) and 75% (aHR, 0.24; 95% CI, 0.03–0.91) lower, respectively, compared with nonvaccinated cases.

Case fatality was significantly higher for 7 individual serotypes (10A, 23A, 19F, 24F, 20, 19A, 11A), compared with that of the second most common serotype 8 (Table 2). Case fatality of serotype 3 was not significantly higher when compared with serotype 8. Serotypes with previously reported high disease potential (serotypes 1, 2, 5, 7F, 12F, 24F, and 38) did not present a higher case fatality (aHR,

Table 1. Distribution of Selected Characteristics/Serotypes Among IPD Cases by Age and Risk Group, SIIPA, France, 2014–2017

Characteristic	Category	Total (n = 908)		18–64 y (n = 321)		65+ y (n = 587)		P	High Risk (n = 335)		At Risk (n = 429)		Healthy (n = 144)		P	
		No.	%	No.	%	No.	%		No.	%	No.	%	No.	%		
Age groups, y	18–49	140	16	-	-	-	-	-	38	11	63	15	39	27	<.001	
	50–64	181	20	-	-	-	-	-	74	22	83	19	24	17		
	65–84	391	43	-	-	-	-	-	171	51	169	39	51	35		
	85+	196	22	-	-	-	-	-	52	16	114	27	30	21		
Residence	Institution	121	13	15	5	106	18	<.001	34	10	40	17	17	11	.035	
Hospitalization in year 1	Yes	368	41	115	36	253	44	.036	197	59	150	35	21	15	<.001	
Severe disease ^b	Yes	431	48	155	49	276	47	.401	159	48	215	50	57	40	.305	
Severe sepsis	Yes	341	38	125	39	216	37	.536	131	39	172	40	38	26	.010	
Shock	Yes	169	19	79	25	90	15	<.001	50	15	102	24	17	12	<.001	
Mechanical ventilation	Yes	190	21	83	26	107	18	.007	58	17	106	25	26	18	.030	
ICU admission	Yes	278	31	124	39	154	26	<.001	97	30	144	36	37	26	.192	
No. of at-risk conditions (excl. smoking & alcoholism)	1–2	485	53	81	32	151	39	<.001	164	49	321	75	0	0	<.001	
	>2	279	31	40	16	140	36	-	171	51	108	25	0	0	-	
Site of infection	Pneumonia	669	74	228	71	441	75	.432	231	69	320	75	118	82	<.001	
	Pleuritis & pn.	67	7	23	7	44	8	-	22	7	40	9	5	4		
	Unkn/other	172	19	70	22	102	17	-	82	25	69	16	21	15		
Chronic lung disease	Yes	187	21	54	17	133	23	.038	66	20	121	28	0	0	<.001	
Smoking (current)	Yes	166	18	121	38	45	8	<.001	47	14	119	28	0	0	<.001	
Heart failure	Yes	165	18	14	4	151	26	<.001	53	16	112	26	0	0	<.001	
Diabetes mellitus	Yes	166	18	30	9	136	23	<.001	66	20	100	23	0	0	<.001	
Malnutrition	Yes	125	14	33	10	92	16	.024	65	19	60	14	0	0	<.001	
Alcoholism	Yes	115	13	79	25	36	6	<.001	26	8	89	21	0	0	<.001	
Malignant solid tumors (<5 y)	Yes	156	17	49	15	107	18	.258	156	47	0	0	0	0	-	
Hematologic cancer (<5 y)	Yes	116	13	28	9	88	15	.231	116	35	0	0	0	0	-	
Immunosuppressive treatment	Yes	92	10	43	13	49	8	.016	92	28	0	0	0	0	-	
Vaccinated against:	Influenza	215	26	39	13	176	33	<.001	83	27	104	26	28	22	.443	
	Pneumococcus	68	8	17	6	51	10	.050	45	15	21	5	2	2	<.001	
Vaccinated with:	PCV7	2	0.2	1	0.3	1	0.2	.677	1	0.3	1	0.3	0	0	.815	
	PCV13	29	4	8	4	21	4	.343	22	7	7	2	0	0	<.001	
	PPSV23	49	6	11	4	38	7	.043	33	11	14	4	2	2	<.001	
Serotypes included in:	PCV7	42	5	16	5	26	5	.007	19	6	19	5	4	3	.002	
	PCV13 only	207	26	64	21	143	27	-	60	20	106	27	41	31	-	
	PPSV23 only	353	42	150	50	203	38	-	118	39	174	44	61	46	-	
Individual serotypes	Nonvaccine	231	28	70	23	161	30	-	108	35	97	25	26	20	-	
	Other	33 serotypes	137	17	60	20	129	24	.004	95	31	72	18	22	17	<.001
	3	PCV13	123	15	38	13	85	7	-	36	12	69	17	18	14	-
	8	PPSV23 only	77	9	38	13	39	7	-	14	5	51	13	12	9	-
	22F	PPSV23 only	63	8	22	7	41	8	-	21	7	32	8	10	8	-
	19A	PCV13	55	7	42	8	13	4	-	18	6	25	6	12	9	-
	12F	PPSV23 only	50	6	24	5	26	9	-	8	3	26	7	16	12	-
	9N	PPSV23 only	49	6	28	5	21	7	-	17	6	21	5	11	8	-
	15A	Nonvaccine	38	5	25	5	13	4	-	21	7	11	3	6	5	-
	24F	Nonvaccine	29	4	19	4	10	3	-	9	3	13	3	7	5	-
	11A	PPSV23 only	28	3	17	3	11	4	-	13	4	11	3	4	3	-
	20	PPSV23 only	25	3	13	2	12	4	-	8	3	13	3	4	3	-
	23A	Nonvaccine	24	3	15	3	9	3	-	8	3	13	3	3	2	-
	10A	PPSV23 only	21	3	10	2	11	4	-	12	4	7	2	2	2	-
	19F	PCV13	21	3	11	2	10	3	-	7	2	12	3	2	2	-
	6C	Nonvaccine	21	3	19	4	2	0.7	-	6	2	12	3	3	2	-
	35B	Nonvaccine	20	2	16	3	4	1	-	12	4	8	2	0	0	-
	Penicillin nonsusceptible	Yes	166	20	51	17	115	22	.112	83	27	58	15	25	19	<.001
	Erythromycin nonsusceptible	Yes	159	19	46	15	113	21	.039	74	24	59	15	26	20	.009
	Cefotaxime nonsusceptible	Yes	28	3	19	4	9	3	.664	14	5	11	3	3	2	.314

Abbreviations: ICU, intensive care unit; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.




Figure 1. Kaplan-Meier survival estimates for time since diagnosis of all cases of invasive pneumococcal disease by (A) disease severity and (B) number of at-risk conditions.

1.08; 95% CI, 0.57–2.0). However, case fatality among the group of serotypes with previously reported strong associations with fatality was significantly higher compared with the other serotypes (Table 2).

Factors Associated With Severe Nonmeningitis IPD

PCV13 serotypes and PPSV23nonPCV13 serotypes were more likely to induce severe nonmeningitis IPD compared with nonvaccine serotypes (aRR, 1.6; 95% CI, 1.3–1.9; and aRR, 1.2; 95% CI, 1.1–1.4, respectively) (Table 3). Those risks were similar (aRR, 1.5; 95% CI, 1.3–1.9; aRR, 1.3; 95% CI, 1.0–1.5, respectively) when the analysis was

restricted to risk groups, but not for previously healthy individuals (aRR, 1.6; 95% CI, 0.94–2.8; aRR, 0.7; 95% CI, 0.36–1.3, respectively). The risk of severe disease increased with increasing number of at-risk conditions, with those with 1–2 chronic conditions (excluding smoking and alcoholism) and those with >2 conditions having 20% and 30% higher risk of developing severe nonmeningitis IPD, respectively, compared with those without at-risk conditions. Those having received vaccination for seasonal influenza were less likely to develop severe nonmeningitis IPD. Antipneumococcal vaccination did not remain significant (aRR, 0.87; 95% CI, 0.62–1.2).

Table 2. Number of Deaths During Hospitalization Among Cases With Invasive Pneumococcal Disease by Different Factors/Serotypes and Adjusted Hazard Ratios From the Final Parametric Survival Analysis Assuming a Weibull Distribution, France, 2014–2017a

Characteristic	Category	Deaths, No.	Case Fatality, %	Ratio of CFs	95% CI	Adjusted HR	95% CI
Age groups, y	18–49	11	8	Ref	Ref	Ref	Ref
	50–64	37	21	2.6	1.4–4.9	3.7	1.5–9.1
	65–84	72	18	2.3	1.3–4.3	3.5	1.5–9.0
	85+	68	35	4.4	2.4–8.0	9.3	3.7–23
Residence	House	141	18	Ref	Ref	Ref	Ref
	Institution	46	38	2.1	1.6–2.8	2.3	1.5–3.5
Severe IPD ^b	Yes	145	34	3.7	2.7–5.0	-	-
	No	43	9	Ref	Ref	-	-
Severe sepsis	Yes	128	38	3.5	2.7–4.7	2.8	1.8–4.3
	No	60	11	Ref	Ref	Ref	Ref
Shock	Yes	83	49	3.4	2.7–4.3	8.9	5.4–15
	No	105	14	Ref	Ref	Ref	Ref
Mechanical ventilation	Yes	66	35	2.0	1.6–2.6	-	-
	No	122	17	Ref	Ref	-	-
ICU admission	Yes	75	27	1.5	1.2–1.9	0.19	0.11–0.33
	No	112	18	Ref	Ref	Ref	Ref
Level of risk	High risk ^c	80	24	1.7	1.1–2.5	-	-
	At risk ^c	87	21	1.4	0.90–2.2	-	-
	Healthy	21	15	Ref	Ref	-	-
No. of comorbidities	0–2	156	19	Ref	Ref	Ref	Ref
	>2	32	36	1.9	1.4–2.6	1.9	1.1–2.5
Heart failure	Yes	52	32	1.7	1.3–2.3	-	-
	No	136	18	Ref	Ref	-	-
Oxygen therapy at home	Yes	12	41	2.1	1.3–3.3	-	-
	No	176	20	Ref	Ref	-	-
Chronic renal failure	Yes	35	35	1.9	1.4–2.5	-	-
	No	153	19	Ref	Ref	-	-
Solid tumors (<5 y)	Yes	52	33	1.8	1.4–2.4	2.7	1.8–4.0
	No	136	18	Ref	Ref	Ref	Ref
PCV13 vaccination	At least 1 dose	3	10	0.51	0.17–1.0	0.25	0.03–0.91
	None	160	20	Ref	Ref	Ref	Ref
Penicillin nonsusceptible	Yes	45	26	1.4	1.0–1.9	0.57	0.34–0.95
	No	121	18	Ref	Ref	Ref	Ref
Group of serotypes with previously reported ^d :	High case fatality	140	26	5.4	2.3–13	2.9	1.1–8.1
	Medium case fatality	18	16	3.3	1.3–8.6	2.0	1.0–6.2
	Low case fatality	5	5	Ref	Ref	Ref	Ref
Serotype 3	PCV13	25	20	3.9	1.4–11	2.0	0.63–7.1
10A	PPSV23 only	7	33	6.4	2.0–19	27	6.1–119
23A	Nonvaccine	7	29	5.6	1.8–18	18	4.7–72
19F	PCV13	5	24	4.6	1.4–16	12	2.6–56
24F	Nonvaccine	6	21	4.0	1.2–13	8.9	2.2–37
20	PPSV23 only	8	32	6.2	2.0–19	6.6	1.7–26
19A	PCV13	23	42	8.1	3.0–21	5.8	1.6–21
11A	PPSV23 only	9	32	6.2	2.1–18	5.7	1.4–22
Others	(33 serotypes; n < 20)	39	21	3.9	1.5–11	5.0	1.5–17
12F	PPSV23 only	7	14	2.7	0.83–8.7	4.3	0.98–18
15A	Nonvaccine	6	16	3.0	0.91–10	4.2	0.94–18
22F	PPSV23 only	10	16	3.1	1.0–9.3	3.9	0.99–14
35B	Nonvaccine	7	35	6.7	2.2–21	2.5	0.58–11
6C	Nonvaccine	4	19	3.7	1.0–14	2.6	0.50–13
9N	PPSV23 only	8	16	3.1	1.0–10	2.3	0.57–9.4
8	PPSV23 only	4	5	Ref	Ref	Ref	Ref

Abbreviations: CF, case fatality; CI, confidence interval; HR, hazard ratio; ICU, intensive care unit; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.

^aOnly includes factors with a *P* value <.30 in the univariable analysis.

^bSevere IPD = either admitted to an ICU or were under mechanical ventilation or had severe sepsis or shock.

^cAt-risk group = immunocompetent with a chronic medical condition; high-risk group = immunosuppression due to malignancy, hemopathy, autoimmune disease, immunosuppressive therapy, asplenia, sickle cell disease, nephrotic syndrome, transplantation and other cause of immunosuppression, or cochlear implant.

^dSerotypes were grouped according to their potential for causing death in previous studies [22–27]; high case fatality = 3, 19A, 12F, 9N, 24F, 11A, 20, 23A, 10A, 19F, 6C, 35B, 15B/C, 35F/31, 16F, 17F, 14, 6A, 6B, 18C, 23F; medium = 22F, 15A, 33F, 9V; low = 8, 7F, 1, 4, 5.

Table 3. Number of Severe Cases Among Patients With Invasive Pneumococcal Disease by Selected Factors and Most Prevalent Serotypes, France, 2014–2017

Characteristic	Category	Severe Cases, ^a No.	% ^b	Risk Ratio	95% CI	Adjusted RR	95% CI
No. of comorbidities ^c	0	139	42	Ref	Ref	Ref	Ref
	1–2	243	51	1.2	1.0–1.4	1.2	1.0–1.4
	≥2	49	54	1.3	1.0–1.6	1.3	1.0–1.7
Serotype category	PCV13	148	60	1.5	1.3–1.9	1.6	1.3–1.9
	PPSV23nonPCV13	157	45	1.2	1.0–1.4	1.2	1.1–1.4
	Nonvaccine	90	39	Ref	Ref	Ref	Ref
Influenza vaccination	Yes	86	41	0.81	0.68–0.97	0.77	0.64–0.93
	No	301	50	Ref	Ref	Ref	Ref

Abbreviations: CI, confidence interval; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; RR, risk ratio.

^aSevere case = an IPD case with 1 of the following: ICU admission, shock or sepsis, or mechanical ventilation; risk = high-risk or at-risk case.

^bProportion of cases that were severe.

^cOne of the following comorbidities/conditions: heart disease, chronic lung disease, chronic liver disease, renal failure, chronic neurological disorder, diabetes mellitus, autoimmune disease, malnutrition, history of invasive pneumococcal disease, or pneumococcal pneumonia.

DISCUSSION

Our study indicated a moderate dose response effect of comorbidities on severe outcomes and an effect on mortality for >2 chronic conditions. Although the association between comorbidities and risk of IPD is established, with some studies suggesting that multiple comorbidities may increase the risk of IPD [9, 13], the effect of comorbidities on severe IPD outcomes is less clear. Some studies have reported a significant association between the presence of underlying conditions and mortality following IPD [11, 12], with few reporting a cumulative effect of comorbidities on fatality [14]. However, other studies have suggested no or only a limited impact of comorbidities on case fatality [27], or no convincing association using the Charlson index [28]. Our results reinforce previous findings of an impact of stacking comorbidities on nonmeningitis IPD risk, adding evidence of an effect of stacking comorbidities on poor IPD outcomes, although a moderate one. Taking into account that multiple chronic diseases are more common in older adults (36% of our cases ≥65 years of age had >2 chronic diseases), the additional evidence in this study may inform discussions on recommendations for adult pneumococcal immunization and disease prevention.

The low proportion of vaccinated cases may reflect the low vaccination coverage among risk groups in France, as reported in other countries [29, 30]. In addition, the low uptake among cases with comorbidities that sought health care within the previous year in our study indicates missed opportunities for vaccination. Previous French studies have suggested that the main reason for the low uptake among risk groups was that physicians did not offer pneumococcal vaccination [31]. Implementation of PCV13 in children aged ≤2 years in France led to a marked reduction in the incidence of IPD in adults, with the IPD incidence having decreased by 37% in adults aged 16–64 years and by 28% in adults aged ≥65 years in 2017 compared with 2008–2009 (<https://www.santepubliquefrance.fr/>

[maladies-et-traumatismes/maladies-a-prevention-vaccinale/infections-a-pneumocoque/donnees/#tabs](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-a-prevention-vaccinale/infections-a-pneumocoque/donnees/#tabs)). PCV implementation also influenced the serotype distribution among IPD cases, with the overall incidence of IPD due to PCV7 serotypes significantly decreasing after PCV7 implementation and accounting for 6.7% of all IPD cases in 2017, as compared with 49% in 2001–2002 (before PCV7 implementation). The effectiveness of PCV has been reported to be high even in patients with immunocompromising conditions [32]. Given that 84% of patients were eligible for vaccination, 71% of those were due to PCV13 or PPSV23 serotypes, and assuming a vaccine effectiveness of 45% for PPSV23 [33, 34] to 75% for PCV13 [32], 27%–45% of cases were potentially preventable with the use of those vaccines. Moreover, despite the low number of vaccinated cases involved, vaccination with PCV13 (or any pneumococcal vaccine, but not with PPSV23 alone) was independently associated with reduced fatality in our study after adjusting for other significant factors. Those findings suggest that targeted vaccination for adults remains an integral part of preventive strategies against IPD and underscore the need for promoting vaccination and improving uptake.

Four to 7 years after the implementation of PCV13 in children aged <2 years, 72% of adult nonmeningitis IPD cases were due to vaccine serotypes, 30% due to PCV13 serotypes, and 42% due to PPSV23nonPCV13 serotypes. Our study indicated that PCV13 serotypes, but also PPSV23nonPCV13 serotypes to a lesser extent, significantly increased the risk of severe nonmeningitis IPD outcomes among risk groups. PCV13 serotypes have been previously associated with severe IPD outcomes, but PPSV23nonPCV13 serotypes have been less often reported to cause severe IPD [25, 35–38]. These findings underscore the need to ensure adherence to the current pneumococcal vaccine recommendations, including PCV13 and PPSV23 in series, to reduce the risk of severe IPD in vulnerable groups.

Consistent with the literature, the groups of serotypes previously associated with high or medium fatality also had significantly increased fatality in our study [19]. In contrast, the group of highly invasive serotypes did not account for higher fatality, as previously reported [36]. In addition, our study indicated that 7 individual serotypes were independently associated with fatality (10A, 23A, 19F, 24F, 20, 19A, 11A). PCV13 serotypes 19A and 19F have been consistently associated with higher mortality, increased risk of meningitis, reduced quality-adjusted life-years (QALY), and complicated and necrotizing pneumonia [25, 35–38]. The PPSV23 serotypes 10A and 11A have been previously associated with increased risk of meningitis and reduced QALY, and 11A has also been associated with increased case fatality [6–9, 37]. The nonvaccine serotype 23A and PPVS23 serotype 20 have rarely been associated with increased mortality, although they were occasionally associated with increased risk of meningitis [37]. The nonvaccine serotype 24F, most common in children, was responsible for a significant increase in the incidence of meningitis in <2-year-old children in 2015–2016 in France [39], but an association with higher mortality of this serotype in adults has not been previously reported.

The case fatality observed in our study (21%) was consistent with other recent studies, ranging from 16% [4, 11] to 31% [27]. However, the proportion of cases admitted to the ICU in our study (31%) was higher than that reported elsewhere [32]. This proportion was significantly lower for older age groups. The protective effect of ICU on fatality may reflect the younger age distribution of ICU admitted cases or a better level of care, resulting in a better outcome.

Nonsusceptibility to penicillin was associated with lower fatality in our study. Previous studies have reported conflicting results on this effect [40–44]. Serotypes with low invasive disease potential but high carriage are more often challenged by antibiotics and are more likely to develop resistance to penicillin [40]. Therefore, regardless of clinical management and antibiotic therapy, the protective effect of nonsusceptibility to penicillin might reflect the lower disease potential of penicillin-nonsusceptible serotypes.

We did not identify significant differences in risk of severe disease or death between high-risk and at-risk patients. This is in contrast with IPD incidence studies indicating a dramatic increase of IPD incidence among patients with immunosuppressive conditions compared with at-risk patients [12]. This suggests different patterns in risks of IPD and mortality among vulnerable groups. In addition to host factors, the greater contribution of PCV13 invasive serotypes in at-risk patients in our study compared with high-risk patients may partly explain this discrepancy. Our findings support the change in vaccination policy in 2017 in France, harmonizing the vaccination scheme for both high-risk and at-risk groups [16].

Having a solid tumor in the previous 5 years was the only individual risk condition that remained significantly associated

with increased fatality, as previously reported [9, 11]. In 1 study, the effect of solid-organ malignancies on case fatality was only observed when linked with concurrent chemotherapy [45]. It is not clear from our study whether this effect was due to immunosuppressive treatment or a direct effect due to the decrease in immune functions caused by cancer. The association between living in an LTCF and a fatal outcome might reflect poorer health, worse living conditions, or other factors not accounted for in the analysis.

Our study was prospective, using well-defined risk criteria and bespoke data sets with good hospital-quality data and high data completeness exceeding 92% for almost all the variables. However, it had a number of limitations. First, we did not include meningitis IPD cases that were part of another dedicated study. Meningitis IPD cases may have a higher fatality and a specific tropism for some pneumococcal serotypes, and this may have affected the comparison with other studies. However, during the study period, pneumococcal meningitis accounted for <10% of all IPD cases in France. Second, we only included intrahospital deaths within 30 days of admission, as we did not follow up cases after discharge from the hospital, and we did not link cases with death certificate registers. This may have led to underestimation of case fatality and may limit comparison with other studies. Third, we started follow-up at the time of admission and not at the time of disease onset. The severity of disease at the time of presentation at the hospital may differ among different age or risk groups, affecting their survival probabilities. However, given the severity of IPD, the time elapsed between disease onset and time to admission is likely to be short. Fourth, we did not collect data on antibiotic therapy either before or at admission, or the delay to prescription of antibiotherapy. The current French guidelines recommend prescription of antibiotics as soon as possible within 4–8 hours after admission. Those factors may affect the IPD prognosis or act as potential confounders of different effects on poor outcomes. Finally, we did not use the Charlson index score to assess patients' comorbid conditions and did not take into account the severity of comorbid conditions. However, this score increases with increasing number of at-risk conditions [7].

CONCLUSIONS

In conclusion, our study indicated a moderate cumulative effect of at-risk conditions on severe outcomes following nonmeningitis IPD, adding to the existing body of evidence that can inform discussions on future recommendations for vaccination strategies among aging populations. Vaccine serotypes were more likely to induce severe nonmeningitis IPD outcomes in vulnerable groups. Finally, the considerable missed opportunities for vaccination and the large proportion of potentially preventable IPD cases and deaths highlight the need

for a focused strategy to vaccinate the most at-risk patients for poor IPD-related outcomes and increase vaccine uptake in targeted risk groups.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

We would like to thank all the infectious disease physicians and microbiologists who collected the data. We are grateful to the staff of the NRCP and the ORP team in Limoges (Sandrine LUCE, Carole Grélaud, Marjorie Prouhet-Poux, Eliza Munteanu). We are also acknowledge Scarlett Georges and Naim Ouldali for critically reviewing the manuscript.

SIIPA group. Isabelle Peloux, Olivier Epaulard, Aurélie Haudour, Christine Recule, A. Blachon, Hélène Petitprez, Céline Janssen, Virginie Vitrat, Pauline Tremeaux, J. Ducruet, Laurence Legout, Farid Sifaoui, Marion Levast, Emmanuel Forestier, Tarik Habet, Charlotte Telini, Marc Fabre, Anne Tixier, Isabelle Vray, Mathilde Guillaume, Henry, Pascale Verger, Philippe Lanotte, Cécile Lebrun, C. Carvalhoschneider, Philippe Lanotte, Marie-Frédérique Lartigue, Louis Bernard, Philippe Lanotte, Dr. Laura Courtellemont, Jerome Guinard, Camelia Gubavu, Camille Petillon, Nathalie Brieu, Laurence Maulin, Véronique Vernet-Garnier, Claire Launois, Yohan Nguyen, Yannick Madoux, Christophe Strady, Franck Noel, Simona Pavel, Maxime Thouvenin, Jean-Marc Galempeix, Natahlie Prieur, Stéphanie Mestraltet, Laure Zucchini, Véronique Vernet-Garnier, Pascal Chavanet, Jennifer Tetu, André Pechinnot, Anthony Texier, Jean-Paul Kisterman, Josephine Chapalain, Catherine Simonin, A. Paleau, Martha Benoit, Bianca Podac, Agathe Ogier Desserrey, Jerome Poirot, Guillaume Gautier, Alain Gravet, Joy Mootien, Alain Gravet, Orlando Saraceni, Alain Gravet, Abdo Mohareb.

Financial support. The study was supported by (i) the Société de Pathologie Infectieuse de Langue Française (SPILF; the French Infectious Diseases Society), (ii) Santé Publique France (SpFrance; the French National Public Health Agency), (iii) the European Centre for Disease Prevention and Control (ECDC), and (iv) Pfizer. The Regional Observatories of Pneumococci (Observatoires Régionaux du Pneumocoque) were supported by Pfizer, BioMérieux, and Sanofi.

Disclaimer. All authors are responsible for the study design, data analysis, data interpretation, and writing of the report. Pfizer, BioMérieux, and Sanofi had no role in the study design, data analysis, data interpretation, or writing of the report.

Potential conflicts of interest. J.G. participates in the boards of experts for Sanofi, Pfizer, and MSD. E.V. reports grants from Pfizer during the conduct of the study and personal fees from Pfizer and grants from MSD outside the submitted work. M.C.P. reports institutional grants from Pfizer and Sanofi during the conduct of the study. M.C.P. participated in the board of experts of Biomérieux until 2018. All other authors declared no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Infect Dis* **2018**; 18:1191–210.
2. Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of *Streptococcus pneumoniae* causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. *PLoS One* **2017**; 12:e0177113.
3. Htar MTT, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. *BMC Infect Dis* **2015**; 15:419.

4. Hughes GJ, Wright LB, Chapman KE, et al. Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease. *Epidemiol Infect* **2016**; 144:2654–69.
5. Browall S, Backhaus E, Naucler P, et al. Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types. *Eur Respir J* **2014**; 44:1646–57.
6. Van Hoek AJ, Andrews N, Waight PA, et al. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. *PLoS One* **2012**; 7:e39150.
7. Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. *Clin Infect Dis* **2014**; 59:1066–73. Erratum in: *Clin Infect Dis* **2014**; 59:1812.
8. Sando E, Suzuki M, Furumoto A, et al. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: the Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE). *Vaccine*. **2019**; 37:2687–2693.
9. Kyaw MH, Rose CE Jr, Fry AM, et al; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. *J Infect Dis* **2005**; 192:377–86.
10. Curcio D, Cané A, Isturiz R. Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence. *Int J Infect Dis* **2015**; 37:30–5.
11. Rudnick W, Liu Z, Shigayeva A, et al; Toronto Invasive Bacterial Diseases Network. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011. *Vaccine* **2013**; 31:5863–71.
12. Wagenvoort GH, Knol MJ, de Melker HE, et al. Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, the Netherlands. *Vaccine* **2016**; 34:334–40.
13. Baxter R, Yee A, Aukes L, et al. Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. *Vaccine* **2016**; 34:4293–7.
14. Morton JB, Morrill HJ, LaPlante KL, Caffrey AR. Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with *Streptococcus pneumoniae* infections. *Vaccine* **2017**; 35:1692–7.
15. Ministère des Affaires Sociales et de la Santé. Calendrier des vaccinations et recommandations vaccinales 2017. **2017**. Available at: https://pro.mesvaccins.net/textes/Calendrier_vaccinal_2016.pdf. Accessed 5 August 2019.
16. Ministère des Affaires Sociales et de la Santé. Calendrier des vaccinations et recommandations vaccinales 2017. **2017**. Available at: https://www.mesvaccins.net/textes/calendrier_vaccinations_2017.pdf. Accessed 5 August 2019.
17. Kempf M, Baraduc R, Bonnabau H, et al. Epidemiology and antimicrobial resistance of *Streptococcus pneumoniae* in France in 2007: data from the Pneumococcus Surveillance Network. *Microb Drug Resist* **2011**; 17:31–6.
18. European Commission. Commission Decision 2018/945/EC of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions. *Offic J Eur Union* **2018**; L170/33–L170/34. Accessed 5 August 2019.
19. Levy MM, Fink MP, Marshall JC, et al; International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Intensive Care Med* **2003**; 29:530–8.
20. The European Committee on Antimicrobial Susceptibility Testing. Breakpoints tables for interpretation of MICs and zone diameters. Version 7.1. **2017**. Available at: <http://www.eucast.org>. Accessed 5 August 2019.
21. Varon E, Cohen R, Béchet S, et al. Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. *Vaccine* **2015**; 33:6178–85.
22. Brueggemann AB, Griffiths DT, Meats E, et al. Clonal relationships between invasive and carriage *Streptococcus pneumoniae* and serotype- and clone-specific differences in invasive disease potential. *J Infect Dis* **2003**; 187:1424–32.
23. Hanage WP, Kajjalainen TH, Syrjänen RK, et al. Invasiveness of serotypes and clones of *Streptococcus pneumoniae* among children in Finland. *Infect Immun* **2005**; 73:431–5.
24. Sá-Leão R, Pinto F, Aguiar S, et al. Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype. *J Clin Microbiol* **2011**; 49:1369–75.
25. Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. *PLoS Med* **2009**; 6:e1000081.
26. Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. *Clin Infect Dis* **2010**; 51:692–9.
27. Hanada S, Iwata S, Kishi K, et al. Host factors and biomarkers associated with poor outcomes in adults with invasive pneumococcal disease. *PLoS One* **2016**; 11:e0147877.

28. Askim Å, Mehl A, Paulsen J, et al. Epidemiology and outcome of sepsis in adult patients with *Streptococcus pneumoniae* infection in a Norwegian county 1993–2011: an observational study. *BMC Infect Dis* **2016**; 16:223.
29. Vietri J, Harnett J, Emir B, Chilson E. Uptake of 13-valent pneumococcal conjugate vaccine among US adults aged 19 to 64 years with immunocompromising conditions. *Hum Vaccin Immunother.* **2019**; 1–8. doi:10.1080/21645515.2019.1632683. [Epub ahead of print].
30. Vila-Córcoles A, Ochoa-Gondar O, de Diego C, et al. Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017. *Euro Surveill.* **2019**; 24. doi:10.2807/1560-7917.ES.2019.24.29.1800446.
31. Vandenbos F, Gal J, Radicchi B. Vaccination coverage against influenza and pneumococcus for patients admitted to a pulmonary care service. *Rev Mal Respir* **2013**; 30:746–51.
32. Tomczyk S, Bennett NM, Stoecker C, et al; Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* **2014**; 63:822–5.
33. Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. *PLoS One* **2017**; 12:e0169368.
34. Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. *EClinicalMedicine* **2018**; 6:42–50.
35. Burgos J, Falcó V, Borrego A, et al. Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia. *Clin Microbiol Infect* **2013**; 19:385–91.
36. Pletz MW, Welte T, Klugman KP. The paradox in pneumococcal serotypes: highly invasive does not mean highly lethal. *Eur Respir J* **2010**; 36:712–3.
37. Grabenstein JD, Musey LK. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. *Vaccine* **2014**; 32:2399–405.
38. Shigayeva A, Rudnick W, Green K, et al; Toronto Invasive Bacterial Diseases Network. Association of serotype with respiratory presentations of pneumococcal infection, Ontario, Canada, 2003–2011. *Vaccine* **2016**; 34:846–53.
39. Ouldali N, Levy C, Varon E, et al; French Pediatric Meningitis Network. Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey. *Lancet Infect Dis* **2018**; 18:983–91.
40. Navarro-Torné A, Díaz JG, Hruba F, et al; Invasive Pneumococcal Disease Study Group. Risk factors for death from invasive pneumococcal disease, Europe, 2010. *Emerg Infect Dis* **2015**; 21:417–25.
41. Gouveia EL, Reis JN, Flannery B, et al. Clinical outcome of pneumococcal meningitis during the emergence of penicillin-resistant *Streptococcus pneumoniae*: an observational study. *BMC Infect Dis* **2011**; 11:323.
42. Vallès X, Marcos A, Pinart M, et al. Hospitalized community-acquired pneumonia due to *Streptococcus pneumoniae*. Has resistance to antibiotics decreased? *Chest* **2006**; 130:800–6.
43. Sjöström K, Spindler C, Örtqvist A, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. *Clin Infect Dis* **2006**; 42:451–9.
44. Song JS, Choe PG, Song KH, et al. Risk factors for 30-day mortality in adult patients with pneumococcal bacteraemia, and the impact of antimicrobial resistance on clinical outcomes. *Epidemiol Infect* **2012**; 140:1267–76.
45. Alanee SR, McGee L, Jackson D, et al; International Pneumococcal Study Group. Association of serotypes of *Streptococcus pneumoniae* with disease severity and outcome in adults: an international study. *Clin Infect Dis* **2007**; 45:46–51.